Translating your pipeline
through fit CMC development.

Chemistry, Manufacturing, and Controls (CMC) technical execution, rescue and expertise for small & large molecules.

Drug Substance & Product Operations

Bridging lab-scale prep into scalable, high-yield manufacturing environments.

  • Active Pharmaceutical Ingredient (API) optimization
  • Formulation development & stability profiling
  • Analytical method development and validation scripts

Regulatory Submissions

Drafting and critical technical review of high-stakes documentation to secure clean tracks through regulatory filters.

  • Comprehensive Module 3 technical authorship
  • IND, NDA, and MAA strategy and assembly
  • Response planning for regulatory technical inquiries

Supply Chain & Third-Party Operations

Structuring, vetting, and managing external execution networks to eliminate manufacturing and distribution risk loops.

  • CDMO selection, contract structuring, and operational oversight
  • Tech transfer planning and physical execution mapping
  • Downstream 3PL logistics and commercial launch scale-up

Strategic Technical Diligence

Evaluating technical asset health, identifying underlying pipeline friction, and securing development assets.

  • Venture capital and asset portfolio technical vetting
  • SBIR and deep scientific grant technical drafting
  • Sterilization approach trade-off and cost analyses
Asset: Large-Molecule Biologic Phase: Pre-IND Scale-Up

Resolving Cell Line Tech Transfer Bottlenecks

The Challenge

An early-stage biotech firm experienced critical yield drift and analytical method inconsistencies during a rapid biological drug substance tech transfer to a regional CDMO.

The Execution

Embedded directly into the tech transfer workflow. Re-engineered analytical verification scripts, audited the CDMO bioreactor set-points, and established a clean structural cross-referencing matrix for raw stability data.

The Outcome

Recovered optimal product yield baseline, trimmed 4 months off the projected submission trajectory, and compiled a bulletproof Module 3 package for a successful IND path.

Asset: Small-Molecule NCE Phase: Phase II to Commercial Planning

De-risking a Multi-Vendor 3PL & Manufacturing Architecture

The Challenge

A pharmaceutical client needed to uncouple their API synthesis from their final drug product tableting lines while simultaneously constructing a clean 3PL commercial shipping and storage pipeline.

The Execution

Constructed a unified multi-vendor manufacturing ledger. Spearheaded terminal sterilization validation protocols to permanently bypass high aseptic processing expenditures, and mapped end-to-end 3PL hand-offs.

The Outcome

Designed a completely transparent supply chain blueprint that protected commercial operating margins and completed manufacturing data packages with zero critical quality observations.

Headshot

Chris Sears

Principal Consultant

Chris has 25-years of experience bridging the rocky terrain from drug discovery through phase-appropriate development and all the way to robust commercial manufacturing operations.

Accomplished across both small-molecule pharmaceutical and large-molecule biotech programs with a direct, execution-focused operational style. Chris builds company systems, CDMO supply chains, and submission packages that startups need to successfully navigate CMC drug development.